Category: Markets
Published: 2026-07-06T15:09:03.000Z
Eli Lilly and Company (LLY) experienced a 14% decline in Q1 2026, primarily due to intensifying regulatory and pricing policy challenges, including concerns about "most favored nation" drug pricing and generic GLP-1 competition. Despite these headwinds, RiverPark Large Growth Fund, which holds LLY, remains confident in the company's long-term growth driven by strong volume for Mounjaro and Zepbound, a robust patent portfolio, and leadership in key therapeutic areas. The fund views the current market dislocation as an attractive buying opportunity for one of the world's premier growth franchises in healthcare.
News summary curated and translated by CausifyMarket. Always consult original sources before making any financial decision.